Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! Image source: Getty Images Simply click below to discover how you can take advantage of this. Alan Oscroft | Wednesday, 29th April, 2020 | More on: AZN The AstraZeneca share price is climbing. Here’s why I’d buy today Enter Your Email Address “This Stock Could Be Like Buying Amazon in 1997” See all posts by Alan Oscroft The FTSE 100 crash has included some spectacular falls across the board. Some banking shares have lost around 40% of their value in just a couple of months. Some safer stocks, like supermarkets, have held on to small falls. But AstraZeneca (LSE: AZN) has held up. In fact, its share price has been bucking the trend, up 9% since the Covid-19 collapse started.It’s perhaps not surprising if pharmaceuticals firms do well during the race to find a vaccine. And that’s surely partly behind the AstraZeneca price rise.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…The virus race has helped push up some smaller pharmaceuticals shares way higher than that. Anyone who has owned shares in Novacyt since the start of the year now sits on a 30-bagger. That’s the kind of rare reward you can enjoy if you happen to hold shares in small-cap companies at a fortunate time. But I can’t see the AstraZeneca share price doing that.A surge like Novacyt’s can also lead to pain if those watching the soaring price jump on the bandwagon too late. I think those considering buying shares in the coronavirus test-maker now, after the price has rocketed, should be cautious.AstraZeneca share priceI also wouldn’t use coronavirus hopes as a reason to jump on the AstraZeneca share price either. A number of firms engaged in research will presumably share in any potential benefits from coronavirus treatments. And the benefits will very likely be relatively short term too. At least, I hope they will. I’d rather take a vaccine that sees it off for good than ongoing profits from longer-term treatments.No, I think of the AstraZeneca share price as a way into the firm’s drugs development pipeline. It’s been years since the company, along with GlaxoSmithKline, suffered from the loss of key patents. New boss Pascal Soriot saw the way forward in drug development, and other pursuits were sidelined with that in mind.And that’s what I’m focused on, long-term drug development. That’s surely what’s going to keep the cash rolling in over the coming decades, and the dividends rolling out again and into shareholders’ pockets.First quarterWednesday’s first-quarter update had CEO Soriot speaking of “another quarter of strong growth across every therapy area and region.” The period’s highlights included key progress for oncology drugs Tagrisso and Koselugo, as well as diabetes medication Farxiga. And I think those are likely to provide better longer-term boosts to the AstraZeneca share price than virus treatments.As far as the company’s Covid-19 work goes, it’s donated nine million face masks to healthcare workers so far, and is researching the virus itself. In Soriot’s words: “We hope our efforts to protect organs from damage, mitigate the cytokine storm and the associated hyperinflammatory state, and target the virus prove to be successful.” I couldn’t have put it better myself.Bottom lineOn the financial front, revenue is up 16%, with EPS up 27% (17% and 33% respectively at constant currency). Analysts are forecasting the start of a strong earnings growth spell this year, and I think Wednesday’s news is cause for optimism. The AstraZeneca share price indicates a forward P/E multiple of 25 this year, dropping to 20 next.I think that’s an attractive price for an excellent company. Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. Our 6 ‘Best Buys Now’ Shares I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.